Topic: mergers and acquisitions
As GlaxoSmithKline sees new opportunity for Zejula beyond BRCA-mutated cancers, it's paying a large premium to acquire Tesaro.
Tesaro has reportedly tried to sell itself before, but to no avail. But its newly lowered share price may be sparking some new buyout interest.
Cambrex finalizes $425 million acquisition of dosage-form CDMO Halo Pharma and its two manufacturing plants.
Polisano Pharmaceuticals is now under the control of rail freight group Grampet after the company upped its stake in the drugmaker from 20% to 74%.
Bayer’s new billboards in St. Louis depict the iconic Gateway Arch planted in greenery to celebrate the close of the Monsanto acquisition.
A trial in a Delaware Court this week will determine if Fresenius can cancel its $4.3 billion buyout of competitor Akorn.
J&J and Allergan are among the pharma companies mulling both acquisitions and selloffs, signaling that the M&A boom will continue through 2018.
Shire's ability to market Cinryze for children as young as 6 with HAE. That could help Shire fend off an all-out attack from CSL.
Takeda's loss of market value is being cited by a group of 12 shareholders stepping up to oppose its acquisition of Shire.
J&J, Roche and Pfizer are most flexible in making M&A deals, but AstraZeneca might not be an easy target, a Leerink report shows.